Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- About Us
- Leadership
- Our Founding Legacy
For Patients
- For Patients
- Patient Advocacy
- Rare Stories
- Support Services
Our Research & Pipeline
- Our Research & Pipeline
- Our Research & Pipeline
- Clinical Trials
Our Medicines
- Our Medicines
- Our Medicines
Responsibility
- Our Responsibility
- Our Responsibility
- Global Medical Affairs
- Corporate Giving
Investors & Media
- Investors & Media
- Investor Relations
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Analyst Consensus
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
Careers
- Careers
- Careers

Investors

Press Releases

Press Releases

Year

February 20, 2026

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

February 3, 2026

Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026

About Amicus

For Patients

Our Research & Pipeline
- Our Research & Pipeline
- - Our Medicines
    - Our Medicines

Responsibility

Investors & Media

Careers
- Careers

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2026 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
DPF Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional